Physician

Mark Fasulo, MD

According to 2025 Medicare claims, Mark Fasulo, MD (NPI: 1366686487) practices interventional cardiology in the Beaumont-Port Arthur, TX market, with the plurality of this provider's patient population coming from Jefferson, TX. This provider's primary affiliated billing organization is ADVANCED CARDIOVASCULAR SPECIALISTS, LLP (NPI: 1366416919; TIN: 760564528) and primary practice location at 77702-1513.

Fasulo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,901 traditional Medicare patients, billed 7,654 HCPCS/CPT codes, and received $1,018,797 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 9,076 prescription claims across 1,554 beneficiaries totaling $1,544,623 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 14 claims. Open Payments data shows 34 records totaling $58,588. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $174,277 to $1,544,623. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $25,522 to $1,635.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,695	22,086	$821,415
2016	2,855	30,501	$1,249,167
2017	3,267	30,008	$1,672,498
2018	3,133	26,382	$1,423,973
2019	3,078	19,958	$1,565,439
2020	2,629	13,951	$1,109,466
2021	2,385	14,334	$1,130,864
2022	2,412	10,168	$1,124,792
2023	2,376	8,092	$903,219
2024	1,901	7,654	$1,018,797

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	399	2,631	$174,277
2016	698	5,358	$519,576
2017	1,117	8,743	$1,048,008
2018	1,283	9,547	$1,143,219
2019	1,421	10,205	$1,414,534
2020	1,469	9,990	$1,541,821
2021	1,470	9,768	$1,690,137
2022	1,459	9,622	$1,706,151
2023	1,518	9,820	$1,826,063
2024	1,554	9,076	$1,544,623

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$25,201
2016	11	48	$55,403
2017	N/R	28	$4,088
2018	N/R	68	$4,936
2019	N/R	60	$51,244
2020	N/R	N/R	N/R
2021	N/R	25	$1,128
2022	N/R	25	$1,159
2023	N/R	14	$1,191
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	567	654	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	558	572	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	384	392	$12
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	569	614	$9
J2785	Injection, regadenoson, 0.1 mg	313	1,252	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	674	33,331	$644,138
Xarelto	Rivaroxaban	416	21,820	$401,628
Entresto	Sacubitril/Valsartan	157	6,660	$137,635
Repatha Sureclick	Evolocumab	119	4,585	$85,986
Multaq	Dronedarone Hcl	23	1,485	$34,429

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$543	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$58,045	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Fasulo, MD?

Tedicare shows public-source Medicare data for Mark Fasulo, MD (NPI 1366686487), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Fasulo, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Fasulo, MD?

Mark Fasulo, MD is linked to ADVANCED CARDIOVASCULAR SPECIALISTS, LLP (billing NPI 1366416919) in the available physician profile data.

Does Mark Fasulo, MD have Open Payments data?

Mark Fasulo, MD has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.